|
Rigel Assumes Development Responsibility for Inhaled Asthma Therapy
PR Newswire (press release) SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 … |
View full post on asthma – Google News